Predictive value of minimal residual disease measurement during remission in childhood acute lymphoblastic leukemia: The results of the International-BFM Study Group (I-BFM-SG).

被引：0
|
作者：
Biondi, A
VanDongen, JJM
Seriu, T
PanzerGrumayer, ER
Willemse, MJ
Corral, L
Stolz, F
Bartram, CR
机构：
[1] UNIV MILAN,OSPED S GERARDO,PEDIAT CLIN,MONZA,ITALY
[2] ERASMUS UNIV ROTTERDAM,DEPT IMMUNOL,NL-3000 DR ROTTERDAM,NETHERLANDS
[3] RUPRECHT KARLS UNIV KLINIKUM,INST HUMANGENET & ANTHROPOL,HEIDELBERG,GERMANY
[4] ST ANNA CHILDRENS HOSP,CHILDRENS CANC RES INST,A-1090 VIENNA,AUSTRIA
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1878 / 1878
页数：1
相关论文
共 50 条
  • [1] The treatment of childhood acute lymphoblastic leukemia - The International BFM Study Group experience
    Masera, G
    Gadner, H
    Kamps, WA
    Otten, J
    Philippe, N
    Schuler, D
    Riehm, H
    INTERNATIONAL JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY, 1998, 5 (2-4): : 141 - 144
  • [2] Results of the Randomized I-BFM-SG Trial "Acute Lymphoblastic Leukemia Intercontinental-BFM 2002" in 5060 Children Diagnosed in 15 Countries on 3 Continents
    Stary, Jan
    Zimmermann, Martin
    Campbell, Myriam
    Castillo, Luis
    Dibar, Eduardo
    Donska, Svetlana
    Gonzalez, Alejandro
    Izraeli, Shai
    Janic, Dragana
    Jazbec, Janez
    Konja, Josip
    Kaiserova, Emilia
    Kowalczyk, Jerzy
    Kovacs, Gabor
    Li, Chi-Kong
    Magyarosy, Edina
    Popa, Alexander
    Stark, Batia
    Jabali, Yahia
    Trka, Jan
    Hrusak, Ondrej
    Janotova, Iveta
    Riehm, Hansjoerg
    Masera, Giuseppe
    Schrappe, Martin
    BLOOD, 2011, 118 (21) : 397 - 398
  • [3] Vincristine (VCR)-Dexamethasone (DEXA) pulses for intermediate risk (IR) childhood acute lymphoblastic leukemia (ALL) treated with BFM based protocols: Results of the I-BFM-SG ALL IR 95 study.
    Conter, V
    Valsecchi, MG
    Silvestri, D
    Campbell, M
    Dibar, EA
    Magyarosy, E
    Gadner, H
    Stary, J
    Benoit, Y
    Riehm, H
    Masera, G
    Schrappe, M
    BLOOD, 2005, 106 (11) : 8A - 8A
  • [4] Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia
    Roberts, WM
    Estrov, Z
    Ouspenskaia, MV
    Johnston, DA
    McClain, KL
    Zipf, TF
    NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (05): : 317 - 323
  • [5] Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group
    A Biondi
    MG Valsecchi
    T Seriu
    E D'Aniello
    MJ Willemse
    K Fasching
    A Pannunzio
    H Gadner
    M Schrappe
    WA Kamps
    CR Bartram
    JJM van Dongen
    ER Panzer-Grümayer
    Leukemia, 2000, 14 : 1939 - 1943
  • [6] Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group
    Bader, Peter
    Kreyenberg, Hermann
    Henze, Guenter H. R.
    Eckert, Cornelia
    Reising, Miriam
    Willasch, Andre
    Barth, Andrea
    Borkhardt, Arndt
    Peters, Christina
    Handgretinger, Rupert
    Sykora, Karl-Walter
    Holter, Wolfgang
    Kabisch, Hartmut
    Klingebiel, Thomas
    von Stackelberg, Arend
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (03) : 377 - 384
  • [7] Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features.: A case control study of the International BFM study group
    Biondi, A
    Valsecchi, MG
    Seriu, T
    D'Aniello, E
    Willemse, MJ
    Fasching, K
    Pannunzio, A
    Gadner, H
    Schrappe, M
    Kamps, WA
    Bartram, CR
    van Dongen, JJM
    Panzer-Grümayer, ER
    LEUKEMIA, 2000, 14 (11) : 1939 - 1943
  • [8] Secondary neoplasms subsequent to acute lymphoblastic leukemia in childhood -: Experience of the BFM study group.
    Löning, L
    Kaatsch, P
    Riehm, H
    Schrappe, M
    BLOOD, 1998, 92 (10) : 679A - 679A
  • [9] Outcome of (Novel) Subgroups in 1257 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia (AML) and the Significance of Minimal Residual Disease (MRD) Status: A Retrospective Study By the I-BFM-SG
    Van Weelderen, Romy E.
    Klein, Kim
    Goemans, Bianca F.
    Zwaan, Christian M.
    De Groot-Kruseman, Hester A.
    Abrahamsson, Jonas
    Arad-Cohen, Nira
    Bart-Delabesse, Emmanuelle
    Buldini, Barbara
    De Moerloose, Barbara
    Dworzak, Michael
    Elitzur, Sarah
    Navarro, Jose M. Fernandez
    Gerbing, Robert B.
    Guest, Erin
    Ha, Shau-Yin
    Harrison, Christine J.
    Hasle, Henrik
    Jackson, Kathy
    Kelaidi, Charikleia
    Lapillonne, Helene
    Leverger, Guy
    Locatelli, Franco
    Miyamura, Takako
    Polychronopoulou, Sophia
    Rasche, Mareike
    Rubnitz, Jeffrey E.
    Stary, Jan
    Tomizawa, Daisuke
    Verwer, Femke
    Kaspers, Gertjan J. L.
    BLOOD, 2020, 136
  • [10] PREDICTIVE VALUE OF MRD PRIOR TO ALLOGENEIC SCT IN RELAPSED CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA - ANALYSIS OF THE ALL-REZ BFM GROUP
    Bader, P.
    Eckert, C.
    Kreyenberg, H.
    Reising, M.
    Borckhardt, A.
    Peters, C.
    Henze, G.
    Klingebiel, T.
    Stackelberg, A., V
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (02) : 23 - 23
12345